Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Serum bone resorption markers after parathyroidectomy for renal hyperparathyroidism: correlation analyses for the cross-linked N-telopeptide of collagen I and tartrate-resistant acid phosphatase.

Hung KC, Huang CY, Liu CC, Wu CJ, Chen SY, Chu P, Wu CC, Lo L, Diang LK, Lu KC.

ScientificWorldJournal. 2012;2012:503945. doi: 10.1100/2012/503945.

PMID:
22919331
2.

Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.

Lu KC, Ma WY, Yu JC, Wu CC, Chu P.

Clin Endocrinol (Oxf). 2012 May;76(5):634-42. doi: 10.1111/j.1365-2265.2011.04265.x.

PMID:
22007930
3.

Parathyroidectomy leads to decreased blood lead levels in patients with refractory secondary hyperparathyroidism.

Chu P, Wu CC, Chen CC, Lu KC.

Bone. 2012 May;50(5):1032-8. doi: 10.1016/j.bone.2012.02.011.

PMID:
22373954
4.

Usefulness of bone resorption markers in hemodialysis patients.

Hamano T, Tomida K, Mikami S, Matsui I, Fujii N, Imai E, Rakugi H, Isaka Y.

Bone. 2009 Jul;45 Suppl 1:S19-25. doi: 10.1016/j.bone.2009.03.663.

PMID:
19332165
5.

The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.

Yamada S, Tsuruya K, Yoshida H, Taniguchi M, Haruyama N, Tanaka S, Eriguchi M, Nakano T, Kitazono T.

Clin Endocrinol (Oxf). 2013 Jun;78(6):844-51. doi: 10.1111/cen.12070.

PMID:
23078546
6.

Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.

Lu KC, Tseng CF, Wu CC, Yeung LK, Chen JS, Chao TY, Janckila AJ, Yam LT, Chu P.

Blood Purif. 2006;24(5-6):423-30.

PMID:
16888370
8.

Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction.

De la Piedra C, Díaz Martín MA, Díaz Diego EM, López Gavilanes E, González Parra E, Caramelo C, Rapado A.

Scand J Clin Lab Invest. 1994 Feb;54(1):11-5.

PMID:
8171266
9.

Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.

Zheng CM, Chu P, Wu CC, Ma WY, Hung KC, Hsu YH, Lin YF, Diang LK, Lu KC.

Tohoku J Exp Med. 2012;226(1):19-27.

PMID:
22156488
10.

[Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].

Nowak Z, Konieczna M, Wańkowicz Z.

Pol Merkur Lekarski. 2004 Aug;17(98):138-41. Polish.

PMID:
15603322
11.

The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.

Minisola S, Pacitti MT, Rosso R, Pellegrino C, Ombricolo E, Pisani D, Romagnoli E, Damiani C, Aliberti G, Scarda A, Mazzuoli SF.

J Endocrinol Invest. 1997 Oct;20(9):559-65.

PMID:
9413811
12.

Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.

Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y.

Clin Endocrinol (Oxf). 2008 Aug;69(2):189-96. doi: 10.1111/j.1365-2265.2008.03187.x.

PMID:
18221403
13.

Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.

Bielesz BO, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH, Bieglmayer C, Sunder-Plassmann G.

Clin Biochem. 2014 Sep;47(13-14):1316-9. doi: 10.1016/j.clinbiochem.2014.06.009.

PMID:
24956265
14.

Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family.

Hernández MV, Peris P, Guañabens N, Alvarez L, Monegal A, Pons F, Ponce A, Muñoz-Gómez J.

Calcif Tissue Int. 1997 Jul;61(1):48-51.

PMID:
9192513
15.

Early changes of bone histology and circulating markers of bone turnover after parathyroidectomy in hemodialysis patients with severe hyperparathyroidism.

Yajima A, Tanaka K, Tominaga Y, Ogawa Y, Tanizawa T, Inou T, Otsubo O, Otsubo K.

Clin Nephrol. 2001 Jul;56(1):27-34.

PMID:
11499656
16.

Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.

Koizumi M, Takahashi S, Ogata E.

Anticancer Res. 2003 Sep-Oct;23(5b):4095-9.

PMID:
14666607
17.

[Total parathyroidectomy in treatment of Sagliker syndrome in 10 cases of hemodialysing patients with secondary hyperparathyroidism].

Zhang L, Yao L, Hua Z, Bian WJ, Li WG.

Zhonghua Nei Ke Za Zhi. 2011 Jul;50(7):562-7. Chinese.

PMID:
22041265
18.

Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.

Kurajoh M, Inaba M, Okuno S, Nagayama H, Yamada S, Imanishi Y, Ishimura E, Shoji S, Yamakawa T, Nishizawa Y.

Osteoporos Int. 2011 Mar;22(3):923-30. doi: 10.1007/s00198-010-1262-x.

PMID:
20449572
19.

Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.

Małyszko J, Małyszko JS, Pawlak K, Wołczyński S, Myśliwiec M.

Adv Med Sci. 2006;51:69-72.

PMID:
17357281
20.

Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration.

Mazzaferro S, Chicca S, Pasquali M, Zaraca F, Ballanti P, Taggi F, Coen G, Cinotti GA, Carboni M.

Nephrol Dial Transplant. 2000 Jun;15(6):877-82.

PMID:
10831645
Items per page

Supplemental Content

Support Center